These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20730702)

  • 1. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
    Raja SG
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1066-73. PubMed ID: 20730702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
    Iglarz M; Binkert C; Morrison K; Fischli W; Gatfield J; Treiber A; Weller T; Bolli MH; Boss C; Buchmann S; Capeleto B; Hess P; Qiu C; Clozel M
    J Pharmacol Exp Ther; 2008 Dec; 327(3):736-45. PubMed ID: 18780830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H
    Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
    Sidharta PN; van Giersbergen PL; Dingemanse J
    J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macitentan for the treatment of pulmonary arterial hypertension.
    DuBrock HM; Channick RN
    Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
    Sidharta PN; Krähenbühl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
    Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
    J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macitentan for the treatment of pulmonary arterial hypertension.
    Hong IS; Coe HV; Catanzaro LM
    Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macitentan for the treatment of pulmonary arterial hypertension.
    Sood N
    Expert Opin Pharmacother; 2014 Dec; 15(18):2733-9. PubMed ID: 25385427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macitentan for the treatment of pulmonary arterial hypertension.
    Spikes L; Williamson T; Satterwhite L
    Drugs Today (Barc); 2014 Jun; 50(6):401-6. PubMed ID: 24983588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.
    Raghu G; Million-Rousseau R; Morganti A; Perchenet L; Behr J;
    Eur Respir J; 2013 Dec; 42(6):1622-32. PubMed ID: 23682110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
    Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
    N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
    Bolli MH; Boss C; Binkert C; Buchmann S; Bur D; Hess P; Iglarz M; Meyer S; Rein J; Rey M; Treiber A; Clozel M; Fischli W; Weller T
    J Med Chem; 2012 Sep; 55(17):7849-61. PubMed ID: 22862294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
    Jacobs A; Preston IR; Gomberg-Maitland M
    Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macitentan: first global approval.
    Patel T; McKeage K
    Drugs; 2014 Jan; 74(1):127-33. PubMed ID: 24297706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Channick RN; Sitbon O; Barst RJ; Manes A; Rubin LJ
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):62S-67S. PubMed ID: 15194180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of macitentan for the treatment of pulmonary arterial hypertension.
    Selej M; Romero AJ; Channick RN; Clozel M
    Ann N Y Acad Sci; 2015 Nov; 1358():68-81. PubMed ID: 26291180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin receptor antagonists.
    Motte S; McEntee K; Naeije R
    Pharmacol Ther; 2006 Jun; 110(3):386-414. PubMed ID: 16219361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension.
    Monaco TJ; Davila CD
    Drug Des Devel Ther; 2016; 10():1675-82. PubMed ID: 27274200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
    Belge C; Delcroix M
    Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.